醇耐药性:在Candida中氨基酸替代的模式 醇14α-脱甲基酶
R Shyama Prasad Rao1,2, Larina Pinto3,4, Rajesh P Shastry5
1Center for Bioinformatics, NITTE deemed to be University, Mangaluru, 575018, India. drrsprao@gmail.com.
Antonie van Leeuwenhoek
|April 17, 2025
概括
坎迪达菌中的亚醇耐药性是一个日益严重的问题. 我们的分析显示,已知的耐药性突变分布不均,少数关键突变主导着文献,这表明报告偏差.
科学领域:
- 菌类学 菌类学是指菌类学.
- 生物化学 生化学
- 计算生物学 计算生物学
背景情况:
- 醇抗真菌药物对于治疗坎迪达菌感染至关重要.
- 对醇的耐药性通常来自于固醇14α-脱甲基酶的突变.
- 这些耐药性转移突变的分布和模式尚不清楚.
研究的目的:
- 为了研究氨基酸替代的分布模式,在Candida物种中赋予醇耐药性.
- 为了确定耐药替代物是否集中在醇14α-脱甲基酶内的醇结合位点.
- 为了确定科学文献中关于报告的抗醇突变的潜在偏见.
主要方法:
- 从科学文献中编制了2222种抗醇替代物的综合数据集.
- 对来自七种Candida物种的固醇14α-脱甲基酶进行了计算序列分析.
- 分析了已知耐药替代物的频率和位置,包括特定的部位和残留物.
主要成果:
- 在7个Candida物种的133个部位确定了169个已知的替代物,Candida albicans在97个部位有120个替代物.
- 少数场地 (10) 和替代品 (18),包括Y132F/H和K143R,占报告病例的75%.
- 不到一半的耐药替代部位 (48%) 位于已知的热点地区,只有33%的与醇相互作用的残留物报告了耐药替代.
- 证据表明文献报告存在显著的偏见,特定突变被过度报告,在易受感染的隔离物中发现了"耐药"突变.
结论:
- 在Candida中,醇耐药性突变的特点是少数非常普遍的替代,这表明文献中的潜在报告偏差.
- 耐药替代物并不仅仅位于先前定义的热点区域或醇相互作用区域内.
- 需要进一步的研究来澄清菌中醇耐药性的真实流行率和机制,超越潜在的偏见文献数据.
相关概念视频
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...